RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      High serum allograft inflammatory factor 1 is associated with poor response to TNFα inhibitors in ankylosing spondylitis patients

      한글로보기

      https://www.riss.kr/link?id=T14818303

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract) kakao i 다국어 번역

      Background: Anti-TNFα therapy has been proven to be highly efficacious in ankylosing spondylitis (AS). Considering its high costs and potential risk for adverse events, early detection of non-responders to anti-TNFα agents is critical.
      Objectives: To identify serum markers predicting clinical response to TNFα blockers in AS
      Methods: Baseline gene expression differences were screened by pathway focused gene assays of peripheral blood RNA from 6 AS patients (3 responders and 3 non-responders) before initiating anti-TNFα treatment, and selected results were confirmed by qRT-PCR in 18 patients (11 responders and 7 non-responders). Concentration of corresponding serum protein was measured by ELISA and compared in 69 responders and 48 non-responders. No response to TNFα blocker was
      defined as less than 50% improvement in Bath ankylosing spondylitis disease activity score (BASDAI) at week 14 from baseline.
      Results: Nine candidate genes were selected from gene assays and validated by qRT-PCR. Among these genes, the expression of allograft inflammatory factor 1 (AIF1) was 3.52 fold higher in non-responders than responders (p=0.032). The serum AIF1 level at baseline was significantly higher in BASDAI 50 non-responders; median 32.8 [IQR 20.6;67.3] pg/ml in responders and 54.2 [28.9;91.0] pg/ml in nonresponders
      (p=0.033). AIF1 level of 63.5 pg/ml or more was associated
      with higher risk for BASDAI > 5.0 at week 14 after anti-TNFα treatment (adjusted OR 6.953, p=0.002).
      Conclusion: Baseline serum AIF1 level was higher in TNFα blocker non-responders. After adjusting age and initial BASDAI, high concentration of baseline AIF1 was associated with high disease activity after TNFα blocker treatment. These results suggest that AIF1 may be a novel serum marker for predicting non-responders to anti-TNFα therapy in AS.
      번역하기

      Background: Anti-TNFα therapy has been proven to be highly efficacious in ankylosing spondylitis (AS). Considering its high costs and potential risk for adverse events, early detection of non-responders to anti-TNFα agents is critical. Objectives: T...

      Background: Anti-TNFα therapy has been proven to be highly efficacious in ankylosing spondylitis (AS). Considering its high costs and potential risk for adverse events, early detection of non-responders to anti-TNFα agents is critical.
      Objectives: To identify serum markers predicting clinical response to TNFα blockers in AS
      Methods: Baseline gene expression differences were screened by pathway focused gene assays of peripheral blood RNA from 6 AS patients (3 responders and 3 non-responders) before initiating anti-TNFα treatment, and selected results were confirmed by qRT-PCR in 18 patients (11 responders and 7 non-responders). Concentration of corresponding serum protein was measured by ELISA and compared in 69 responders and 48 non-responders. No response to TNFα blocker was
      defined as less than 50% improvement in Bath ankylosing spondylitis disease activity score (BASDAI) at week 14 from baseline.
      Results: Nine candidate genes were selected from gene assays and validated by qRT-PCR. Among these genes, the expression of allograft inflammatory factor 1 (AIF1) was 3.52 fold higher in non-responders than responders (p=0.032). The serum AIF1 level at baseline was significantly higher in BASDAI 50 non-responders; median 32.8 [IQR 20.6;67.3] pg/ml in responders and 54.2 [28.9;91.0] pg/ml in nonresponders
      (p=0.033). AIF1 level of 63.5 pg/ml or more was associated
      with higher risk for BASDAI > 5.0 at week 14 after anti-TNFα treatment (adjusted OR 6.953, p=0.002).
      Conclusion: Baseline serum AIF1 level was higher in TNFα blocker non-responders. After adjusting age and initial BASDAI, high concentration of baseline AIF1 was associated with high disease activity after TNFα blocker treatment. These results suggest that AIF1 may be a novel serum marker for predicting non-responders to anti-TNFα therapy in AS.

      더보기

      목차 (Table of Contents)

      • I. Introduction 1
      • II. Subjects and Methods 4
      • III. Results 11
      • IV. Discussion 30
      • V. References 35
      • I. Introduction 1
      • II. Subjects and Methods 4
      • III. Results 11
      • IV. Discussion 30
      • V. References 35
      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼